WallStSmart

Maravai Lifesciences Holdings Inc (MRVI)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Maravai Lifesciences Holdings Inc generates 27492% more annual revenue ($204.73M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -51.1%. MRVI earns a higher WallStSmart Score of 31/100 (F).

MRVI

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.32

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRVI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.5%10/10

Revenue surging 40.5% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

MRVI4 concerns · Avg: 2.8/10
Operating MarginProfitability
1.1%3/10

Operating margin of 1.1%

Debt/EquityHealth
1.283/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-49.4%2/10

ROE of -49.4% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRVI

The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MRVI

The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

MRVI profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.38 — expect wider price swings.

MRVI is growing revenue faster at 40.5% — sustainability is the question.

MRVI generates stronger free cash flow (4M), providing more financial flexibility.

Bottom Line

MRVI scores higher overall (31/100 vs 24/100) and 40.5% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Maravai Lifesciences Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?